CGL
NGNE icon

Clarius Group LLC’s Neurogene NGNE Stock Holding History

Clarius Group LLC’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,176
Closed -$15K – 530
2022
Q3 		$15K Hold
1,176
– – ﹤0.01% 492
2022
Q2 		$24K Hold
1,176
– – ﹤0.01% 467
2022
Q1 		$113K Hold
1,176
– – 0.01% 486
2021
Q4 		$113K Sell
1,176
-4
-0.3% -$487 0.01% 486
2021
Q3 		$171K Buy
1,180
+4
+0.3% +$612 0.02% 413
2021
Q2 		$217K Hold
1,176
– – 0.02% 379
2021
Q1 		$289K Sell
1,176
-146
-11% -$37.3K 0.03% 292
2020
Q4 		$373K Buy
1,322
+146
+12% +$35.7K 0.04% 219
2020
Q3 		$282K Buy
+1,176
New +$285K 0.04% 221

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Clarius Group LLC's NGNE Position: Q4 2022 in Review

Clarius Group LLC sold out of Neurogene (NGNE) in Q4 2022, closing a stake of 1,176 shares — an estimated $15K sold.

Clarius Group LLC first reported a position in NGNE in Q3 2020 and held it in 9 quarters. The position peaked at $373K in Q4 2020. 45 funds tracked by Wall St. Rank hold NGNE as of Q4 2022.

  • Clarius Group LLC reported no remaining Neurogene position as of Q4 2022 after selling out during the quarter.
  • Clarius Group LLC sold 1,176 Neurogene shares in Q4 2022, an estimated $15K.
  • Clarius Group LLC first reported a position in Neurogene in Q3 2020 and held it in 9 quarters.
  • Clarius Group LLC's Neurogene position peaked at $373K in Q4 2020.
  • 45 funds tracked by Wall St. Rank held Neurogene as of Q4 2022.

Based on Clarius Group LLC's 13F filing for Q4 2022, filed 25 Jan 2023.